parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.07 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in retinal pigment epithelial cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	9 Parkinson's papers of 3,072	0.70
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 3901

receipt 3909: BMP7 in dopamine neurons, braak

power: full sample -0.23 (p 0.355, n 18), 95% CI -0.63 to +0.26. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.20 (p 0.434, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.32 (p 0.201, n 18). could be the mix.
skeptic: leave-one-out range -0.36 to -0.13, sign flips 0; without severely affected donors -0.23 (p 0.355, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for BMP7 in dopamine neurons.

case closed: nothing better to follow up.

receipt 3908: BMP7 in oligodendrocytes, braak

power: full sample -0.40 (p 0.097, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.44 (p 0.067, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.66 (p 0.0029, n 18). not the mix.
skeptic: leave-one-out range -0.50 to -0.32, sign flips 0; without severely affected donors -0.40 (p 0.097, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for BMP7 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts